| Name | Title | Contact Details |
|---|
Aerolase designs, manufactures and markets the LightPod family of lasers, which represent a technology breakthrough in the field of laser medicine. The result is a new generation of aesthetic and dermatology lasers, built on the proven safety and versatility of gold-standard medical laser modalities. LightPod lasers deliver the highest power for aesthetic & dermatology treatments with uniquely optimized laser pulse parameters based on clinical research. They lead the industry with an unprecedented combination of Efficacy, Safety, Versatility, and Return on Investment.
Biosensors International-Usa is a Newport Beach, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
1 800 Any lens is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
II-VI Incorporated, a global leader in engineered materials and optoelectronic components, is a vertically integrated manufacturing company that develops innovative products for diversified applications in the industrial, optical communications, military, life sciences, semiconductor equipment, and consumer markets. Headquartered in Saxonburg, Pennsylvania, the Company has research and development, manufacturing, sales, service, and distribution facilities worldwide. The Company produces a wide variety of application-specific photonic and electronic materials and components, and deploys them in various forms, including integrated with advanced software to enable our customers.
Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.